{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:19Z","timestamp":1768867219445,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ygyno.2021.08.005","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T09:29:27Z","timestamp":1629278967000},"page":"57-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial"],"prefix":"10.1016","volume":"163","author":[{"given":"Mathew","family":"Cowan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy M.","family":"Swetzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valery","family":"Adorno-Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario J.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki L.","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Lurain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohreh","family":"Shahabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Taiym","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn Lucrezia","family":"O'Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masha","family":"Kocherginsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.08.005_bb0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdx011","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer InterGroup: first-line interventions","volume":"28","author":"Karam","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0010","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN guidelines insights: ovarian cancer, version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0015","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0020","article-title":"Multi-institutional phase 2 study of TLK286 (TELCYTATM, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer","volume":"15","author":"Kavanagh","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.005_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju029","article-title":"Better therapeutic trials in ovarian cancer","volume":"106","author":"Bookman","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0030","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1535-7163.MCT-20-0277","article-title":"Phase I, Pharmacogenomic, drug interaction study of Sorafenib and Bevacizumab in combination with paclitaxel in patients with advanced refractory solid tumors","volume":"19","author":"Chiorean","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ygyno.2011.08.033","article-title":"Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I\/II study of the Hoosier oncology group","volume":"123","author":"Ramasubbaiah","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0040","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2021.08.005_bb0045","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/386671a0","article-title":"Mechanisms of angiogenesis","volume":"386","author":"Risau","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2021.08.005_bb0050","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1535-7163.MCT-07-0237","article-title":"Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer","volume":"6","author":"Huynh","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0055","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bcp.2007.09.029","article-title":"Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis","volume":"75","author":"Selvakumaran","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0060","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0065","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0070","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0075","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0080","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0090","doi-asserted-by":"crossref","first-page":"45954","DOI":"10.1038\/srep45954","article-title":"Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells","volume":"7","author":"Momeny","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0095","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejca.2017.06.018","article-title":"A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma","volume":"83","author":"Vergote","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.005_bb0100","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1586\/14737140.2015.1081383","article-title":"Pazopanib in ovarian cancer","volume":"15","author":"McLachlan","year":"2015","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0110","doi-asserted-by":"crossref","first-page":"44075","DOI":"10.1038\/srep44075","article-title":"Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells","author":"Momeny","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0115","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12197","article-title":"Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors","volume":"104","author":"Niwakawa","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0120","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2011.35.3524","article-title":"Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma","volume":"30","author":"Nosov","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0125","series-title":"R: A Language and Environment for Statistical Computing","author":"Core Team","year":"2020"},{"key":"10.1016\/j.ygyno.2021.08.005_bb0130","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1158\/1078-0432.CCR-11-0411","article-title":"Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, \u22122, and \u22123 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors","volume":"17","author":"Eskens","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0135","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/cpdd.113","article-title":"A phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors","volume":"3","author":"Moore","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-013-2632-9","article-title":"A phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer","volume":"140","author":"Mayer","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0145","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11060-016-2332-5","article-title":"Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma","volume":"131","author":"Kalpathy-Cramer","year":"2017","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2018.02.009","article-title":"Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study","volume":"94","author":"Molina","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.005_bb0155","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.2019.37.7_suppl.541","article-title":"TIVO-3: a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)","volume":"37","author":"Rini","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10555-011-9337-5","article-title":"Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer","volume":"31","author":"Masoumi Moghaddam","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0170","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10456-005-9001-1","article-title":"Angiogenesis in normal and neoplastic ovaries","volume":"8","author":"Ramakrishnan","year":"2005","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ygyno.2021.08.005_bb0175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3835(97)00350-9","article-title":"Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas","volume":"121","author":"Hartenbach","year":"1997","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0180","first-page":"3001","article-title":"Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma","volume":"23","author":"Gadducci","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0185","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1158\/1078-0432.CCR-07-1888","article-title":"Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?","volume":"14","author":"Duncan","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0190","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2018.05.029","article-title":"A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology\/gynecologic oncology group study (GOG-254)","volume":"150","author":"Chan","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.005_bb0200","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821006508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821006508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:59:26Z","timestamp":1758772766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821006508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0090825821006508"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}